# Enhanced Genetic Targeting of Specific Neuronal Populations Using a Minipromoter and Splicing Hybrid Approach

> **NIH NIH R21** · TUFTS UNIVERSITY BOSTON · 2024 · $468,126

## Abstract

PROJECT SUMMARY. Current AAV-based methods to target inhibitory interneurons, and their subpopulations,
remain too leaky to use with recombinases such as Cre. Furthermore, the specificity of the widely used CaMKII
minipromoter to access excitatory neurons also displays off-target expression. The long-term goal of this project
is to develop ultra-specific AAVs that can overcome leakage into non-target cells and therefore be compatible
with recombinase enzymes. The overall objective of this application is to develop and test hybrid AAVs that
harness alternative splicing, through splicing linked expression design (SLED), in combination with current state-
of-the-art minipromoters and enhancers. The central hypothesis is that this hybrid approach will increase target
specificity, enabling the delivery of recombinases like Cre. The rationale for the project is to generate and share
novel tools to speed up basic science research and reduce the reliance on knockin and transgenic Cre lines to
target distinct populations of neurons. Increasing the specificity of AAVs would also benefit future gene therapy
interventions, where highly controlled gene expression is essential. The central hypothesis will be tested by
pursuing two specific aims: 1) Design and rigorously evaluate the ability of miniaturized enhancer-SLED hybrid
constructs to deliver Cre with increased specificity; and 2) Generate sequencing datasets from subcortical brain
regions to uncover cell type-specific splicing events. Under the first aim, cell-specific exons for inhibitory
interneurons (INs), parvalbumin positive interneurons (PV-INs), and excitatory neurons (ENs) will be identified
and utilized to make hybrid SLED AAVs with existing minipromoters or enhancers. These AAVs will be screened
in vitro, then leading candidates will be thoroughly tested in vivo in mice to rigorously evaluate their specificity.
For the second aim, the RiboTag technology will be used to isolate bulk RNA samples from ENs and PV-INs from
the amygdala and thalamus, allowing high depth RNA sequencing to map patterns of cell and region-specific
alternative splicing. This will enable integration with published cortical and hippocampal datasets so that region-
specific alternative splicing patterns can be identified. This will further a basic scientific understanding of
alternative splicing and support the future development of SLED vectors targeting subcortical cell populations
relevant to psychiatric disease. The proposed research is innovative because it combines SLED with the leading
enhancer and minipromoter technologies to create hybrid AAV constructs predicted to achieve a level of
specificity beyond what is possible with each individual approach. This proof of principle experiment could open
new horizons for the subpopulations of cells that can be targeted genetically. Furthermore, this research project
will generate a valuable dataset tailored to comparing alternative splicing across cell types and brain regi...

## Key facts

- **NIH application ID:** 10987600
- **Project number:** 1R21NS135454-01A1
- **Recipient organization:** TUFTS UNIVERSITY BOSTON
- **Principal Investigator:** Alexei Mansfield Bygrave
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $468,126
- **Award type:** 1
- **Project period:** 2024-07-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10987600

## Citation

> US National Institutes of Health, RePORTER application 10987600, Enhanced Genetic Targeting of Specific Neuronal Populations Using a Minipromoter and Splicing Hybrid Approach (1R21NS135454-01A1). Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/grant/nih/10987600. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*